<DOC>
	<DOCNO>NCT02726581</DOCNO>
	<brief_summary>This phase 3 multicenter , randomize , open label study design evaluate clinical benefit safety combination therapy Nivolumab , pomalidomide , dexamethasone ( N-Pd investigational arm , compare pomalidomide dexamethasone ( Pd ; control arm ) subject relapse refractory multiple myeloma ( rrMM ) . The study include third arm evaluate clinical benefit safety combination therapy elotuzumab , nivolumab , pomalidomide dexamethasone ( NE-Pd , exploratory arm ) patient population . Subjects control arm ( Pd ) allow cross-over exploratory arm ( EN-Pd ) time progression .</brief_summary>
	<brief_title>Study Combinations Nivolumab , Elotuzumab , Pomalidomide Dexamethasone Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Refractory relapse refractory multiple myeloma Measurable disease Have receive â‰¥ 2 line prior therapy must include immune modulatory drug ( IMiD ) proteasome inhibitor alone combination Solitary bone extramedullary plasmacytoma disease Active plasma cell leukemia Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>